UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 22, 2014
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-36172 |
|
22-3106987 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
26 Landsdowne Street,
Cambridge, Massachusetts |
|
02139 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (617) 494-0400
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 1.01 |
Entry into a Material Definitive Agreement. |
On December 22, 2014, ARIAD
Pharmaceuticals, Inc. (ARIAD) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) entered into a Collaboration Agreement (the Collaboration Agreement) for Otsuka to commercialize ARIADs Iclusig® (ponatinib) in Japan and nine other Asian countries (collectively, the Territory) and to fund future clinical trials in those countries.
ARIAD will lead the completion of the Japanese New Drug Application (NDA) for Iclusig, and Otsuka will file the NDA on behalf of
both companies for regulatory approval in resistant and intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL), which is planned to occur in 2015. Iclusig is an approved BCR-ABL inhibitor
in the United States, Europe and Australia.
Under the terms of the Collaboration Agreement, Otsuka will have an exclusive license to
market Iclusig in the Territory and to perform certain development activities, at its expense. Otsuka will have exclusive commercial rights to Iclusig and will promote it as its sole tyrosine kinase inhibitor in the Territory. In addition, Otsuka
will purchase Iclusig from ARIAD in bulk form, or potentially in final packaged form for certain countries, in dosage strengths approved in the Territory. The countries that are included in the Collaboration Agreement are Japan, China, South Korea,
Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam.
In consideration for the exclusive license and other
rights contained in the agreement, Otsuka has agreed to make an upfront payment of $77.5 million to ARIAD, a milestone payment upon regulatory approval in Japan for patients with resistant and intolerant Philadelphia-positive leukemias, and
additional milestone payments for approval in other indications. ARIAD will also be entitled to receive royalties and other payments representing a substantial share of net product sales. Following approvals in the Territory, Otsuka will conduct
sales activities and record sales.
ARIAD has agreed to continue to fund the completion of its ongoing pivotal trial of Iclusig that will
form the basis of the filing for regulatory approval in Japan, while Otsuka has agreed to fund additional agreed-upon clinical studies in the Territory. For ARIAD-sponsored global studies that include sites in Japan, Otsuka has the option to
contribute to the funding and gain access to the data for use in the Territory.
Unless terminated earlier, the Collaboration Agreement
has a term that continues until the later of (x) the expiration of all royalty obligations in the Territory, or (y) the last sale by Otsuka or its sublicensees of a product in the Territory under approvals obtained under the agreement. The
Collaboration Agreement may be terminated (i) by either party based on insolvency or uncured breach by the other party or an unresolved, extended force majeure event affecting the other party, (ii) by Otsuka at its discretion on 180 days
prior written notice, or (iii) by ARIAD upon the failure of Otsuka to submit an application for marketing authorization or launch Iclusig in Japan within specified dates, assuming such failure is not due to ARIADs failure to meet certain
obligations, or other reasons beyond Otsukas control.
ARIAD and Otsuka will establish a joint development and commercialization
committee (JDCC) to oversee clinical development and commercialization of Iclusig in the Territory, including approval of any development or commercialization plans. Each party has ultimate decision making authority with respect to a
specified limited set of issues, and for all other issues, the matter must be resolved by consensus or by an expedited arbitration process.
The foregoing description of the Collaboration Agreement does not purport to be complete and is qualified in its entirety by reference to such
agreement, which ARIAD intends to file as an exhibit to its Annual Report on Form 10-K for the year ending December 31, 2014. A copy of the press release announcing the Collaboration Agreement is attached to this Current Report on Form 8-K as
Exhibit 99.1 and is incorporated herein by reference.
2
ITEM 9.01 |
Financial Statements and Exhibits |
(d) The following exhibits are filed with this report:
|
|
|
Exhibit
Number |
|
Description |
|
|
99.1 |
|
Press Release dated December 23, 2014. |
THE PRESS RELEASE CONTAINS HYPERTEXT LINKS TO INFORMATION ON OUR WEBSITE AND/OR OTHER WEBSITES. THE INFORMATION ON OUR
WEBSITE AND ANY OTHER WEBSITE IS NOT INCORPORATED BY REFERENCE INTO THIS CURRENT REPORT ON FORM 8-K AND DOES NOT CONSTITUTE A PART OF THIS FORM 8-K.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
ARIAD Pharmaceuticals, Inc. |
|
|
By: |
|
/s/ Edward M. Fitzgerald |
|
|
Edward M. Fitzgerald |
|
|
Executive Vice President, Chief Financial Officer |
Date: December 30, 2014
4
Exhibit 99.1
News Release
ARIAD AND OTSUKA ANNOUNCE CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR
ICLUSIG® TO TREAT LEUKEMIAS IN JAPAN AND NINE OTHER ASIAN COUNTRIES
|
|
ARIAD to receive upfront payment of USD 77.5 million and subsequent milestone-based payments |
|
|
Otsuka to obtain rights in ten Asian countries to Iclusig, a newest-generation treatment for patients with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia |
Cambridge, MA and Tokyo, Japan December 23, 2014 ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ: ARIA) and Otsuka Pharmaceutical Co., Ltd.
(Otsuka) today announced that they have entered into an agreement for Otsuka to commercialize ARIADs Iclusig® (ponatinib) in Japan and nine other Asian countries and to fund future
clinical trials in those countries. ARIAD will lead the completion of the Japanese New Drug Application (NDA) for Iclusig, and Otsuka will file the NDA on behalf of both companies for regulatory approval in resistant and intolerant chronic myeloid
leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) in 2015. Iclusig is an approved BCR-ABL inhibitor in the United States, Europe and Australia.
The agreement provides for Otsuka to receive exclusive rights to market Iclusig in Japan and nine other Asian countries (the Territory) in return
for an upfront payment of $77.5 million to ARIAD, a milestone payment upon regulatory approval in Japan for patients with resistant and intolerant Philadelphia-positive leukemias, and additional milestone payments for approval in other indications.
Following approvals in the Territory, Otsuka will conduct sales activities and record sales. ARIAD will also receive a substantial share of net product
sales.
ARIAD will continue to fund the completion of its ongoing pivotal trial of Iclusig that will form the basis of the filing for regulatory approval
in Japan, while Otsuka will fund additional agreed-upon clinical studies in the Territory. For ARIAD-sponsored global studies that include sites in Japan, Otsuka has the option to contribute to the funding and gain access to the data for use in the
Territory.
This agreement meets one of our key strategic objectives establishing a strong partnership with an
experienced and committed Japanese pharmaceutical company to commercialize and co-develop Iclusig in Japan and Asia, said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. Otsuka is building a leading hematology and
oncology business in Japan and Asia and is an outstanding partner to successfully commercializing Iclusig in these markets.
Over the past
several years, we have worked with the leading hematology experts in Japan and have run the Phase 1/2 clinical trial that will form the basis for our marketing authorization application, he added. Together with Otsuka, we will be able to
make this cancer medicine available to refractory Philadelphia-positive leukemia patients in need of new treatment options.
Otsuka Pharmaceutical
President and Representative Director Taro Iwamoto noted, The future arrival of ARIADs ponatanib in Japan and elsewhere in Asia will be an important evolution for patients with CML and Philadelphia-positive ALL with BCR-ABL gene
expression, said to be particularly difficult to treat. Treatments have been inadequate for patients with these life-threatening conditions and we aim to contribute to improve the treatment available to them. ARIADs high-level drug discovery
technology powered its discovery of ponatanib and Otsuka aims to maintain this momentum by making it part of our expanded portfolio in blood cancers from pre-treatment conditioning to treatments.
A joint development and commercialization committee will oversee clinical development and commercialization of Iclusig in the Territory, including approval of
any development or commercialization plans. Otsuka will have exclusive commercial rights to Iclusig and will promote it as its sole tyrosine kinase inhibitor in the Territory. In addition to Japan, the other Asian countries that are included in this
agreement are China, South Korea, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam.
About Iclusig® (ponatinib) tablets
Iclusig is a kinase inhibitor discovered by ARIAD. The primary
target for Iclusig is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig was designed using ARIADs computational and
structure-based drug-design platform specifically to inhibit the activity of BCR-ABL. Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has
been associated with resistance to other approved TKIs.
Important U.S. Safety Information for
Iclusig® (ponatinib)
WARNING: VASCULAR OCCLUSION, HEART FAILURE, and HEPATOTOXICITY
2
See full U.S. prescribing information for complete boxed warning
|
|
Vascular Occlusion: Arterial and venous thrombosis and occlusions have occurred in at least 27% of Iclusig-treated patients, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of
the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients less than 50 years old, experienced these events. Monitor for evidence of
thromboembolism and vascular occlusion. Interrupt or stop Iclusig immediately for vascular occlusion. A benefit risk consideration should guide a decision to restart Iclusig therapy. |
|
|
Heart Failure, including fatalities, occurred in 8% of Iclusig-treated patients. Monitor cardiac function. Interrupt or stop Iclusig for new or worsening heart failure. |
|
|
Hepatotoxicity, liver failure and death have occurred in Iclusig-treated patients. Monitor hepatic function. Interrupt Iclusig if hepatotoxicity is suspected. |
Please see the full U.S. Prescribing Information for Iclusig, including the Boxed Warning, for additional important safety information.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered
in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various
forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional
information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: Otsuka-people creating new products for better health
worldwide. Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs in several under-addressed diseases
including several cancer categories and tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a big venture company at heart, applying a youthful spirit of
creativity in everything it does.
3
Otsuka Pharmaceutical Co., Ltd., which employs approximately 28,700 people worldwide, is a wholly owned
subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group that is headquartered in Tokyo, Japan. The Otsuka Group has business operations in 27 countries and regions around the world, with consolidated sales of approximately
USD 14.1 billion for fiscal year 2013 (4/1/2013-3/31/2014.) Otsuka Pharmaceutical welcomes you to visit its global website at https://www.otsuka.co.jp/en.
ARIAD Forward-Looking Statements
This press release
contains forward-looking statements which are based on managements good-faith expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to
differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to the Companys ability to manufacture and supply Iclusig to Otsuka; the ability of Otsuka to perform the
contracted services, such as obtaining marketing authorizations, other regulatory approvals, and pricing and reimbursement approvals for Iclusig in the countries covered by the collaboration agreement (Territory); Otsukas ability
to distribute, promote, market and sell Iclusig in the Territory; Otsukas ability to fund the clinical development of Iclusig in the Territory; the timing and scope of the marketing authorizations obtained in the Territory, as well as the
level of pricing obtained in Territory; third-party reimbursement; and the timing and success of sales of Iclusig in the Territory. These factors, risks and uncertainties also include, but are not limited to the costs associated with ARIADs
development and manufacturing, commercial and other activities; the adequacy of capital resources and the availability of additional funding; and other factors detailed in the Companys public filings with the U.S. Securities and Exchange
Commission. The information contained in this press release is believed to be current as of the date of original issue. After the date of this document, the Company does not intend to update any of the forward-looking statements to conform to actual
results or to changes in the Companys expectations, except as required by law.
|
|
|
|
|
|
|
For Investors |
|
For Media |
Contacts at ARIAD |
|
Kendra Adams Kendra.adams@ariad.com
(617) 503-7028 |
|
Liza Heapes Liza.heapes@ariad.com
(617) 621-2315 |
|
|
|
Contacts at Otsuka |
|
Yoko Ishii Ishiiyo@Otsuka.jp
+81 3 6361 7411 |
|
Jeffrey Gilbert
Gilbert.jeffrey@Otsuka.jp +81 3 6361 7379, +81 80 8728
6039 |
4
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2024 to May 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From May 2023 to May 2024